Dolphin Vagal Nerve Stimulation for COVID-19
Covid-19 is an infectious disease that may lead to Acute Respiratory Distress Syndrome (ARDS), which is characterized by widespread inflammation in the lungs, inflammatory cytokine storms, (Guo 2020; Zhou 2020), and respiratory dysfunction. (Busl 2015, Liu 2017). COVID-19-related mortality is mostly due to the inability to resolve infection and inflammatory responses which can spread through the bloodstream to cause multiorgan failure. (Kaniusas 2020)
The vagus nerve, the major nerve of the parasympathetic nervous system, mediates the immune response to inflammatory processes in the body (Pavlov 2012), and controls pulmonary function to regulate breathing (Chang 2015).
New COVID Treatment: Non-Invasive Vagus Nerve Simulation
Electrically stimulating the auricular branch of the vagus nerve (ABVN) has been proven in science to activate the parasympathetic system (Clancy 2014), reducing lung inflammation (Kaniusas 2019), and pro-inflammatory cytokines to improve respiratory dysfunction (Tracey, 2007). So potent is this approach, that non-invasive electrical stimulation of the vagus nerve can be clinically effective in counteracting Covid-19 respiratory complications (Kaniusas 2020)
In a recently published study titled “Non-invasive Auricular Vagus Nerve Stimulation as a Potential Treatment for Covid19-Originated Acute Respiratory Distress Syndrome” it was reported “There is a large body of clinical and preclinical data that support the favorable effects of auricular vagus nerve stimulation in inflammation, sympatho-vagal balance as well as in respiratory and cardiac ailments with COVID patients” (Kaniusas 2020).
Conclusion: Non-invasive Auricular Vagus Nerve Stimulation can help combat acute COVID-19 related ARDS
Health Canada Approved: Dolphin Vagal Nerve Stimulation for COVID-19
Health Canada March/2021: Dolphin Vagal Nerve Stimulator (VNS) is NOW authorized for emergency use in the acute treatment of adult patients with known or suspected COVID-19.
Dolphin VNS is intended for those who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, using non-invasive VNS applied to the auricular branch of the vagus nerve (ABVN) during the COVID-19 pandemic to help with symptom relief. (Canada.ca Link)
Health Canada recognizes the severity of Covid-19 complications, especially ARDS, can be reduced by triggering a “natural endogenous systemic brake” of the pulmonary inflammatory response though application of the Dolphin VNS to the auricular branch of the vagus nerve (ABVN).
Dolphin VNS is a safe clinical procedure and could be an effective treatment for ARDS originated by Covid-19 and similar viruses. Dolphin’s unique ability to “detect” and treat key vagal activating points within minutes (>10 min), provides a new “window of opportunity” for any clinical or hospital or Long Term Care (LTC) setting battling with COVID-19.
Dolphin VNS enables the introduction of a potentially lifesaving intervention which can be safely administered by any health care professional or clinical staff with minimal training or supervision. Subsequent improved immune system functioning provided by Dolphin VNS could significantly reduce the need for hospitalization and mechanical ventilation, which are the major determinants of healthcare collapse.
Conclusion: Dolphin Vagal Nerve Stimulation (VNS) is a safe clinical proven procedure which could be an effective treatment for managing ARDS originated by Covid-19 and similar viruses.
Note: Starting March 19, 2024, Health Canada will be rescinding the expanded use indications granted during the COVID-19 pandemic as there is no longer an urgent public health need for devices related to COVID-19.
Purchase Dolphin VNS
Dolphin VNS is currently only available for purchase in Canada. If you are interested in purchasing the Dolphin VNS in USA, please fill out the form below.
